因美纳致力于改进我们预测遗传疾病的方式,以改善早期临床干预、治疗和结果为目标奋斗。我们努力开展具有开创性的研究,为具有不同种族背景、性别和社会阶层的大小群体提供帮助。
推动基于多基因风险评分的研究发展
因美纳致力于改进我们预测遗传疾病的方式,以改善早期临床干预、治疗和结果为目标奋斗。我们努力开展具有开创性的研究,为具有不同种族背景、性别和社会阶层的大小群体提供帮助。
符合条件的申请者受邀提交一份新项目摘要(不超过400字),其中需描述如何结合使用Infinium Global Diversity Array with PRS Content-8 v1.0 Kit及Illumina Polygenic Risk Score软件的预测模块。
针对感兴趣的疾病或表型,利用已有评分或新创建的评分执行相关计算和风险预测,具备可靠的报告能力,可推动研究进展。
该资助计划向学术、营利或非营利机构的基因组学基础研究人员开放
申请者需提交400字以内的书面摘要,包含研究概述、工作陈述,以及研究将产生的影响。摘要最多可包含3张图(带图例)和1个引用列表(200字以内)。
Publication of Project Results:
All grant submissions are confidential to the individual submitter and will not be published or distributed, provided, however, Allelica and Illumina may share them with their own staff and distributors, who will not disclose them to third parties. Allelica and Illumina may both support the grant advertising efforts.
The winner will be selected by a panel of judges selected by Allelica and Illumina. The panel may include representatives from Allelica and Illumina. Upon project completion, the grant winner agrees to participate in at least one of the following activities relating to the specific project, with specific details of the applicable activity to be mutually agreed upon in good faith by Allelica, Illumina, and the winner: webinar, case study, blog post, poster presentation, or conference presentation. The winner agrees that Illumina shall have the right to publicly announce the winner’s name and research title and use anonymized data from the winner's projects in application notes including in marketing materials and seminars- no public display of data will happen without prior consent from the winner.
By submitting a grant application, each applicant agrees that Allelica and Illumina may use his or her name, abstract title, for marketing purposes.
All grant applicants agree that Allelica and Illumina may process the personal data he or she provides as part of application, including sharing such data with Illumina’s partners, collaborators and other third parties who are obligated to keep the data confidential, and in accordance with Illumina’s privacy policies.
Applicants agree that Illumina may use applicant’s names, email addresses and affiliated institution to contact applicants for purposes of marketing of its products and services in accordance with the Illumina privacy policy here.
The grant award winner may be required to sign and return an affidavit of eligibility, release of liability, a publicity release, and other appropriate legal documentation reasonably requested by Illumina. No substitution or transfer of the awarded prize is allowed except as permitted by Illumina. The award winner is responsible for any local tax liability (city, state, or federal) occurred by winning and accepting the award. If, for any reason, the grant program may not run as planned for any causes beyond the reasonable control of Illumina, then Illumina reserves the right in its sole discretion to cancel, terminate, modify or suspend the grant program. These terms and conditions and any action related to this grant program will be governed by the laws of the State of California without regard to or application of its conflict of law provisions or your state or country of residence. All claims, legal proceedings or litigation arising in connection with these terms and conditions and this grant program will be brought solely in the federal or state courts located in San Diego County, California, and all applicants consent to the jurisdiction of and venue in such courts and waive any objection as to inconvenient forum. By participating in this grant program, each applicant unconditionally accepts and agrees to comply with and abide by these terms and conditions.
申请资料应包括以下信息:
为确保您提交资料的有效性,所有报名材料必须:
评判标准:
由科学家和主管组成的小组将对所有提交的资料进行评审。我们会根据项目反映的科学价值、创新性以及与因美纳价值观的匹配程度来评判每一份提交资料。
2023年因美纳多基因风险评分研究资助的申请工作正在进行中。申请资料提交的截止日期为太平洋时间2023年7月31日晚11:59。
专家组将从所有合格的申请中评选出一名获奖者,申请排名的标准如下:
获胜者将获得1008个Infinium Global Diversity Array样本,以及PRS Content-8 v1.0试剂盒和随附的分析软件,总价值超过100,000美元(奖品)。考虑生物医学多样性的研究提案将获得优先考虑。
华盛顿大学医学院,密苏里州圣路易斯
因美纳祝贺华盛顿大学医学院精神病学助理教授Emma Johnson博士获得2024年因美纳多基因风险评分研究资助。她和同事们利用因美纳和Allelica技术对1000名手术患者进行基因分型,研究术后急性疼痛向慢性疼痛的转变。本研究将开发慢性疼痛和阿片类药物使用障碍的多基因风险评分,以改善疼痛管理和降低阿片类药物相关风险,应对重大公共卫生挑战。